You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Med-X Inc.
Med-X is gearing up for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before public health adoption accelerates.
In certain use cases, Med-X's all-natural pesticides have outperformed chemical brands in independent lab tests, delivering safer solutions without sacrificing results.
Now, Med-X is approaching a major real-world validation catalyst: Florida Mosquito Control Districts are independently testing Nature-Cide as an adulticide, larvicide, and barrier treatment – with the goal of adding it to their official rotation.
Florida has the most well-funded mosquito control districts in the United States and carries the highest responsibility for controlling mosquito-borne threats. These districts are known as leaders and innovators in Integrated Mosquito Management – meaning that when Florida adopts a solution, other regions often follow.
And right now, these districts need better options.
Public scrutiny over the chemical pesticides traditionally used in mosquito control is rising fast – especially around communities, schools, and waterways. Nature-Cide's plant-based approach offers a potential alternative that aligns with performance demands while reducing toxicity concerns.
Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, and agricultural sectors. Proudly produced in the USA under strict quality standards, Nature-Cide reflects their commitment to sustainable pest management innovation.
With $6.4M in sales in just four years, expanding into 41 international markets, Med-X is getting ready for the next step...
This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that this is a paid advertisement for Med-X's Regulation A+ Offering and we have received or expect to receive compensation in connection with the disbursing this communication for Med-X . The compensation could consist of $4,025.00 or more and was received/will be received from Investing Media Solutions.
This communication should not be considered as an endorsement of Med-X and we are not responsible for any errors or omissions in any information provided about by or about Med-X.
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
This disclosure is made as of 02/24/2026.
Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribehere.
Tidak ada komentar:
Posting Komentar